...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Prevention of nonsteroidal inflammatory drug-induced urticaria and/or angioedema
【24h】

Prevention of nonsteroidal inflammatory drug-induced urticaria and/or angioedema

机译:预防非甾体类炎症性药物引起的荨麻疹和/或血管性水肿

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Urticaria and/or angioedema (U/AE) are the most frequent and less severe forms of nonallergic hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). Management of NSAID-induced U/AE includes (1) the avoidance of the culprit drug and of cyclooxygenase (COX) 1 inhibitors, (2) the use of weak COX-2 inhibitors, and/or (3) desensitization to aspirin. Because these possibilities may have drawbacks, we tested the possibility of preventing NSAID-induced U/AE by the administration of antihistamines and/or a combination of antihistamines and leukotriene antagonists. Objective: To test the preventive effect of antihistamines and/or leukotriene antagonists on the development of U/AE in patients with a history of NSAID hypersensitivity confirmed by a positive challenge result. Methods: A single, placebo-controlled, oral challenge using the culprit NSAID was applied to 65 patients with a history of NSAID-induced U/AE. In the case of recurrence of the symptoms, another oral challenge was performed under premedication with antihistamines alone or combined antihistamines and leukotriene antagonists. Results: A total of 59 of 65 patients (90%) tolerated a normal dose of NSAID, confirming previous data on the poor reproducibility of nonallergic hypersensitivity reactions to NSAIDs on challenge. Of the 6 patients who experienced recurrence of the U/AE on NSAID challenge, antihistamines and combined antihistamines and leukotriene antagonists prevented the hypersensitivity reactions in 2 and 3 of them, respectively. Only 1 patient still developed a moderate NSAID-induced urticaria despite the double premedication. Conclusion: Treatment with NSAIDs at normal doses is possible and well tolerated in patients who have experienced NSAID-induced U/AE, which could be prevented by the concomitant use of antihistamines and leukotriene antagonists.
机译:背景:荨麻疹和/或血管性水肿(U / AE)是对非甾体类抗炎药(NSAIDs)发生的最常见,最不严重的非过敏性超敏反应。 NSAID诱导的U / AE的管理包括(1)避免使用罪魁祸首药物和环氧合酶(COX)1抑制剂,(2)使用弱COX-2抑制剂,和/或(3)对阿司匹林脱敏。因为这些可能性可能有缺点,所以我们测试了通过施用抗组胺药和/或抗组胺药和白三烯拮抗剂的组合来预防NSAID诱导的U / AE的可能性。目的:测试抗组胺药和/或白三烯拮抗剂对NSAID超敏史患者的U / AE发展的预防作用,该结果由阳性攻击结果证实。方法:对65名有非甾体抗炎药诱导的U / AE病史的患者使用单用安慰剂对照的口服非甾体抗炎药进行口服攻击。在症状复发的情况下,在单独使用抗组胺药或联合使用抗组胺药和白三烯拮抗剂的预用药下进行另一次口服攻击。结果:65名患者中有59名(90%)耐受正常剂量的NSAID,这证实了以前关于非过敏性非过敏性反应对NSAIDs重复性差的先前数据。在因NSAID攻击而经历U / AE复发的6例患者中,抗组胺药以及抗组胺药和白三烯拮抗剂的组合分别预防了其中2和3个患者的超敏反应。尽管有双重处方,但只有1例患者仍出现中度NSAID引起的荨麻疹。结论:在经历了NSAID诱导的U / AE的患者中,可以以正常剂量使用NSAID治疗,并且耐受性良好,可以通过同时使用抗组胺药和白三烯拮抗剂来预防。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号